PH26372A - Novel medicinal use of 5-(2-chloroethyl)-4-methylthiazole or a salt or solvate thereof - Google Patents
Novel medicinal use of 5-(2-chloroethyl)-4-methylthiazole or a salt or solvate thereof Download PDFInfo
- Publication number
- PH26372A PH26372A PH40041A PH40041A PH26372A PH 26372 A PH26372 A PH 26372A PH 40041 A PH40041 A PH 40041A PH 40041 A PH40041 A PH 40041A PH 26372 A PH26372 A PH 26372A
- Authority
- PH
- Philippines
- Prior art keywords
- prevention
- treatment
- methylthiazole
- chloroethyl
- solvate
- Prior art date
Links
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 150000003839 salts Chemical class 0.000 title claims description 11
- 239000012453 solvate Substances 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 230000002265 prevention Effects 0.000 claims abstract description 26
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 7
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 201000004810 Vascular dementia Diseases 0.000 claims description 7
- 230000007954 hypoxia Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- HXVHKHDEUMNKRY-UHFFFAOYSA-N 2-(2-chloroethyl)-4-methyl-1,3-thiazole Chemical compound CC1=CSC(CCCl)=N1 HXVHKHDEUMNKRY-UHFFFAOYSA-N 0.000 claims 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960004414 clomethiazole Drugs 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 241000699694 Gerbillinae Species 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymerization Catalysts (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8900564A SE8900564D0 (sv) | 1989-02-17 | 1989-02-17 | Novel medicinal use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26372A true PH26372A (en) | 1992-06-01 |
Family
ID=20375091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH40041A PH26372A (en) | 1989-02-17 | 1990-02-12 | Novel medicinal use of 5-(2-chloroethyl)-4-methylthiazole or a salt or solvate thereof |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0458892B1 (sv) |
| JP (1) | JP3007683B2 (sv) |
| KR (1) | KR0139221B1 (sv) |
| AT (1) | ATE107166T1 (sv) |
| AU (1) | AU643431B2 (sv) |
| CA (1) | CA2045618A1 (sv) |
| DE (1) | DE69009989T2 (sv) |
| DK (1) | DK0458892T3 (sv) |
| ES (1) | ES2055421T3 (sv) |
| HK (1) | HK44597A (sv) |
| IE (1) | IE64622B1 (sv) |
| IL (1) | IL93243A (sv) |
| NZ (1) | NZ232499A (sv) |
| PH (1) | PH26372A (sv) |
| SE (1) | SE8900564D0 (sv) |
| WO (1) | WO1990009174A1 (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP921128B1 (en) * | 1991-10-30 | 1998-10-31 | Sandor Garaczy | Novel process for the preparation of 4-methyl-5(2-chloroethyl)-thiazole and analogues thereof |
| SE9802119D0 (sv) * | 1998-06-15 | 1998-06-15 | Astra Ab | New use |
| SE9901658D0 (sv) * | 1999-05-06 | 1999-05-06 | Astra Ab | New formulation |
| SE9904177D0 (sv) * | 1999-11-18 | 1999-11-18 | Astra Ab | Novel compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE196140C1 (sv) * | 1964-01-01 |
-
1989
- 1989-02-17 SE SE8900564A patent/SE8900564D0/sv unknown
-
1990
- 1990-02-01 IL IL9324390A patent/IL93243A/en not_active IP Right Cessation
- 1990-02-09 IE IE46090A patent/IE64622B1/en not_active IP Right Cessation
- 1990-02-12 PH PH40041A patent/PH26372A/en unknown
- 1990-02-13 CA CA002045618A patent/CA2045618A1/en not_active Withdrawn
- 1990-02-13 WO PCT/SE1990/000093 patent/WO1990009174A1/en active IP Right Grant
- 1990-02-13 NZ NZ232499A patent/NZ232499A/xx unknown
- 1990-02-13 DE DE69009989T patent/DE69009989T2/de not_active Expired - Lifetime
- 1990-02-13 EP EP90903980A patent/EP0458892B1/en not_active Expired - Lifetime
- 1990-02-13 ES ES90903980T patent/ES2055421T3/es not_active Expired - Lifetime
- 1990-02-13 AU AU51679/90A patent/AU643431B2/en not_active Ceased
- 1990-02-13 JP JP2503995A patent/JP3007683B2/ja not_active Expired - Lifetime
- 1990-02-13 DK DK90903980.2T patent/DK0458892T3/da active
- 1990-02-13 AT AT90903980T patent/ATE107166T1/de not_active IP Right Cessation
-
1991
- 1991-08-16 KR KR91700916A patent/KR0139221B1/ko not_active IP Right Cessation
-
1997
- 1997-04-10 HK HK44597A patent/HK44597A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL93243A0 (en) | 1990-11-29 |
| CA2045618A1 (en) | 1990-08-18 |
| DE69009989D1 (de) | 1994-07-21 |
| NZ232499A (en) | 1992-12-23 |
| ES2055421T3 (es) | 1994-08-16 |
| DK0458892T3 (da) | 1994-08-15 |
| KR0139221B1 (en) | 1998-05-15 |
| IE64622B1 (en) | 1995-08-23 |
| HK44597A (en) | 1997-04-18 |
| KR920700641A (ko) | 1992-08-10 |
| JP3007683B2 (ja) | 2000-02-07 |
| SE8900564D0 (sv) | 1989-02-17 |
| AU5167990A (en) | 1990-09-05 |
| ATE107166T1 (de) | 1994-07-15 |
| DE69009989T2 (de) | 1994-10-13 |
| WO1990009174A1 (en) | 1990-08-23 |
| EP0458892B1 (en) | 1994-06-15 |
| EP0458892A1 (en) | 1991-12-04 |
| IE900460L (en) | 1990-08-17 |
| IL93243A (en) | 1994-08-26 |
| AU643431B2 (en) | 1993-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69100282T3 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| US20210069159A1 (en) | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | |
| WO2021218638A1 (zh) | 用于糖尿病及其并发症治疗的联合用药及其药物组合物 | |
| EP2114398B1 (en) | Isosorbide mononitrate derivatives for the treatment of ocular hypertension | |
| JPS6154006B2 (sv) | ||
| WO2001082919B1 (en) | Methods of and compounds for inhibiting calpains | |
| PH26372A (en) | Novel medicinal use of 5-(2-chloroethyl)-4-methylthiazole or a salt or solvate thereof | |
| CN105963244A (zh) | 注射用青蒿琥酯制剂及其应用 | |
| US8513280B2 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
| IE64936B1 (en) | Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis | |
| DE60017733T2 (de) | Verwendung von riluzol zur behandlung multipler sklerose | |
| KR100342367B1 (ko) | 녹내장치료제및안압강하제 | |
| EP1410808A1 (en) | Optic nerve protecting agents containing alpha 1 receptor blocker as the active ingredient | |
| WO1998016224A1 (de) | Pyrazolinone zur behandlung von potenzstörungen | |
| US5399572A (en) | Chlormethiazole in the treatment of neurodegeneration | |
| CN1200710C (zh) | 大环内酯类化合物的新用途 | |
| US20080194466A1 (en) | (5Z)-5-(6-Quinoxalinylmethylidene)-2-[(2,4,6-Trichlorophenyl)Amino]-1,3-Thiazol-4(5H)-One | |
| JPH04503512A (ja) | 新規な医薬用途 | |
| Chen | Aliphatic versus aromatic amines as vasoconstrictors | |
| US6291493B1 (en) | Treatment of spinal cord injuries | |
| Midtvedt | Penicillins, cephalosporins and tetracyclines | |
| WO2021035289A1 (en) | Therapeutic methods and uses thereof | |
| EP0874840A1 (en) | Dibenzothiepin derivatives and pharmaceutical compositions |